Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2024 06:00 ET | Source: Coave Therapeutics

Coave Therapeutics Showcases Breakthrough in Peptide-Based Conjugated AAV Vectors Using ALIGATER™ Platform in a Late-Breaking Abstract at ESGCT 2024

Coave’s proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid,...
September 24, 2024 06:00 ET | Source: Coave Therapeutics

Coave Therapeutics to Present Novel Data Highlighting the Potential of its ALIGATER™ Platform to Enhance the Targeted Delivery of Genetic Medicines at Upcoming Conferences

Paris, France, September 24, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company pioneering therapies for eye and neurodegenerative diseases, will present the first data on its...
May 07, 2024 03:00 ET | Source: Coave Therapeutics

EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...
April 29, 2024 06:00 ET | Source: Coave Therapeutics

Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroidal Route

coAAV-mediated gene transfer holds promise for expanding the scope of ocular diseases treatable via suprachoroidal administration Data to be presented in oral session at ASGCT 2024 Paris,...
April 25, 2024 06:00 ET | Source: Coave Therapeutics

eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies,...
March 27, 2024 07:00 ET | Source: Coave Therapeutics

Coave Therapeutics to Present at Upcoming Conferences

Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following...
February 29, 2024 07:00 ET | Source: Coave Therapeutics

Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS

CTx-TFEB is a novel, targeted genetic medicine approach designed to promote autophagy and reduce the accumulation of toxic protein aggregates in neurons Funding aims to support the progression of...
October 12, 2023 07:00 ET | Source: Coave Therapeutics

Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform

Paris, France, October 12th, 2023– Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces the formation of its new Scientific Advisory Board...
September 28, 2023 08:15 ET | Source: Coave Therapeutics

Coave Therapeutics to Present at Upcoming Conferences

Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
September 21, 2023 06:00 ET | Source: Coave Therapeutics

Coave Therapeutics Appoints Genetic Medicine Expert Lolita Petit, PhD as Chief Scientific Officer

Paris, France, September 21, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...